Latest news with #Macular
Malaysian Reserve
18-07-2025
- Business
- Malaysian Reserve
Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031
NEW YORK, July 18, 2025 /PRNewswire/ — According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing significantly with the increasing prevalence of ocular diseases. The global preservative-free eye drops market is expected to reach US$1.67 billion in 2031 from US$1.21 billion in 2024. The market is estimated to grow at a CAGR of 4.3% from 2025 to 2031. The increasing prevalence of ocular diseases, the aging global population, surging awareness for chemical-free products, and supportive regulations and recommendations fuel market growth. However, limited availability of such products in the market and shorter shelf life hinder market growth. To explore the valuable insights in the Preservative Free Eye Drops Market report, you can easily download a sample PDF of the report – The preservative-free eye drops market is segmented on the basis of type, application, and distribution channel. The report runs an in-depth analysis of market trends, key players, and future opportunities. Overview of Report Findings Increasing Prevalence of Ocular Diseases: Age-related complications such as cataracts, glaucoma, and macular degeneration are among the top causes of vision loss globally. As per the report 'Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment' published in 2022, age-related macular degeneration impacts over 200 million people worldwide and is expected to reach 300 million by 2040. As per the WHO 2023, in Europe, approximately 90 million people have some form of vision impairment or blindness, representing ~9% of the population. The prevalence of these complications highlights the need for efficient eye care treatment. Preservative-free eye drops provide a safer option for people suffering from chronic eye diseases, reducing the risk of preservative-related irritation and toxicity. Rising Aging Population: With age, individuals become more prone to dry eye syndrome, glaucoma, age-related macular degeneration, and cataracts. These disorders need to be treated long-term or even for a lifetime through ophthalmic solutions. But conventional preservative-containing eye drops such as those containing benzalkonium chloride (BAK), are known to induce or worsen irritation, inflammation, and injury to the ocular surface, particularly with prolonged use. Elderly patients are susceptible to such side effects because of thinner tear films and lower regenerative capacity of the ocular surface. Preservative-free eye drops, which provide a milder and safer option, are increasingly being favored among this population. The tendency is particularly prominent in industrialized nations with an accelerating aging population, including Japan, Germany, and the US. It is also gaining prominence in China and India. Clinicians today are inclined to prescribe preservative-free drugs for older patients with chronic diseases. With the world population aged 60 and above expected to double by the year 2050, demand for safer, better-tolerated ophthalmic products will surge, driving market growth. For Detailed Preservative Free Eye Drops Market Insights, Visit: Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR in the preservative free eye drops market during the forecast period. Market Segmentation By type, the preservative free eye drops market is segmented into single dose and multiple dose. The single-dose segment held a larger share of the market in 2024, and it is anticipated to register the highest CAGR in the market during 2025–2031. Based on application, the preservative free eye drops market has been segmented into dry eye disease (DED), eye allergy/ infection, glaucoma, retinal disorders, and other indications. The dry eye disease segment held the largest share of the market in 2024 and is expected to register a higher CAGR in the market during 2025–2031. In terms of distribution channel, the preservative free eye drops market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024. The online pharmacies segment is expected to register the highest CAGR in the market during 2025–2031. The preservative free eye drops market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Stay Updated on The Latest Preservative Free Eye Drops Market Trends: Competitive Strategy and Development Key Players: Major companies operating in the preservative free eye drops market are Nemera, Alcon Inc., Bausch & Lomb Incorporated, Eyekare Kilitch Ltd., Essex Bio-Technology Limited, Pillar5 Pharma Inc., iVIZIA, Allergan PLC, CorneaCare Inc. Trending Topics: Dry Eye Disease (DED) Treatment, Glaucoma Therapeutics, Allergic Conjunctivitis Treatment, Contact Lens Care Products, Ophthalmic Surgical Products, Natural and Organic Eye Care Products, Pediatric Eye Care, etc. Global Headlines on Preservative Free Eye Drops Market Lumify Preservative Free Redness-Reducing Eye Drops Launch in US Alcon Announces US Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Long-Lasting Formula Purchase Premium Copy of Global Preservative Free Eye Drops Market Size and Growth Report (2021-2031) at: Conclusion The preservative free eye drops market is growing, driven primarily by the rising prevalence of chronic ocular diseases, an aging global population, and increasing consumer awareness of the adverse effects associated with preservatives. Advances in sterile packaging technologies have made preservative-free formulations more accessible and convenient. Additionally, soaring demand for safer, natural, and more tolerable eye care products aligns with broader healthcare and lifestyle trends. However, higher production costs and limited availability in certain regions limit growth. Overall, the market's future looks promising as healthcare providers and consumers prioritize ocular safety and comfort, making preservative-free eye drops a vital segment in the evolving ophthalmic therapeutics landscape. The report from The Insight Partners lists several stakeholders—including manufacturers, healthcare providers, distributors and suppliers, and regulatory bodies—along with valuable insights on how to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: The Allergy Relieving Eye Drops Market Size is expected to register a CAGR of 4.2% from 2025 to 2031 Eye Drops and Lubricants Market Size, Trends, Shares, and Forecast – 2031 Dry Eye Disease Market Size is expected to register a CAGR of 5.6% from 2025 to 2031 Diabetic Eye Disease Equipment Market Size, Trends, Shares, and Forecast – 2031 Dry Eye Disease Diagnostic Devices Market Size, Trends, Shares, and Forecast – 2031 The eye allergy treatment market size is projected to reach US$ 5.69 billion by 2030 Retinal Surgery Devices Market Size is expected to register a CAGR of 5.9% from 2025 to 2031 Retinal Implant Market Size is expected to register a CAGR of 8.4% from 2025 to 2031 The Thyroid Eye Disease Treatment Market Size is expected to register a CAGR of 6.3% from 2025 to 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876Press Release – More Life Sciences Research Reports & Industry Analysis – Logo: View original content:
Yahoo
15-05-2025
- Health
- Yahoo
Age-Related Macular Degeneration (AMD) Market Forecast Report and Company Analysis 2025-2033 Featuring Hoffmann - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharma, Bausch, Alimera Science
The aging population, rising rates of lifestyle-related risk factors, improved diagnostic tools, more awareness, and the creation of novel AMD treatments and therapies are the main factors propelling the Age-Related Macular Degeneration (AMD) market. Age-Related Macular Degeneration (AMD) Market Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Macular Degeneration (AMD) Market is expected to reach US$ 20.88 billion by 2033 from US$ 11.42 billion in 2024, with a CAGR of 6.94% from 2025 to 2033 In affluent societies, age-related macular degeneration (AMD) is the primary cause of blindness in older adults. It is an age-related eye condition that gradually impairs the central vision required for reading, driving, facial recognition, and color vision. As AMD worsens, central vision is lost, impairing quality of life by preventing many patients from reading, writing, or recognizing color and detail. Recent advancements in genetic technologies have led to the discovery of several variants that have been demonstrated to have distinct relationships with AMD, despite the fact that the precise functional pathophysiology of AMD is still macula, the core portion of the retina, gradually degenerates in age-related macular degeneration, resulting in central vision loss. Based on its clinical characteristics, such as drusen, aberrant pigmentation, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV), age-related macular degeneration can be categorized as early, intermediate, or late. Another way to describe age-related macular degeneration is as wet (exudative or neovascular) or dry (atrophic or non-neovascular).The market is expected to be primarily driven by the introduction of new products, a robust product pipeline, and an increase in the prevalence of AMD. According to the Population Reference Bureau, the number of Americans 65 and older is expected to increase by 47%, from 58 million in 2022 to 82 million in 2050. Today, the U.S. population is older than it has ever of the main elements driving category expansion is the aging population. About 200,000 new cases of wet AMD are discovered in North America each year, according to Genentech. Wet AMD causes 90 percent of legal blindness but only accounts for about 10 percent of events. Because of the unchecked proliferation of new blood vessels in the eye, which results in fluid leaking into the macula, this advanced variety can cause rapid and severe vision Drivers for the Age-Related Macular Degeneration (AMD) Market Innovative Treatment OptionsThe management of age-related macular degeneration (AMD) has changed dramatically as a result of the introduction of novel medications, including as anti-VEGF (vascular endothelial growth factor) therapy. These therapies have been shown to stabilize or enhance vision in a large number of patients by preventing aberrant blood vessel formation in the retina, which is a defining feature of wet AMD. Furthermore, by focusing on the genetic defects that cause AMD, advances in gene therapy hold the promise of treating the disease's underlying causes. The market is expanding as a result of these new treatment options, which can delay the course of AMD and enhance patients' quality of life. It is anticipated that more ground-breaking treatments will surface as research progresses, increasing the range of available treatments and improving patient AwarenessGrowing public knowledge of age-related macular degeneration (AMD) is a major factor in the market's growth. The public is being educated about the symptoms, risk factors, and significance of early diagnosis through awareness programs run by patient advocacy organizations, healthcare organizations, and ophthalmology experts. People are more inclined to seek early screening as they become more knowledgeable about the illness, which can result in earlier therapies that can improve outcomes. More people are identifying AMD in its early stages thanks to better access to healthcare, especially in poorer nations. The market for AMD is developing as a result of increased awareness and proactive healthcare strategies, which are driving up demand for diagnostic and treatment Healthcare InvestmentsNew and better treatments for Age-Related Macular Degeneration (AMD) are being developed more quickly thanks to increased funding for ophthalmology and retinal research. More research into improved diagnostic methods, cutting-edge treatments, and even cures for AMD is being made possible by increased funding from the public and commercial sectors. Additionally, this investment is supporting clinical trials for potential medications and therapies that could provide better treatments for both wet and dry forms of AMD. The market for AMD is seeing the introduction of innovative treatments and diagnostic tools due to technological breakthroughs and an increasing emphasis on retinal health. These developments will ultimately improve patient care and propel market in the Age-Related Macular Degeneration (AMD) Market High Treatment CostsPatients may need repeated injections over long periods of time, and treatments for Age-Related Macular Degeneration (AMD), particularly anti-VEGF medications, can be costly. Both patients and healthcare systems may experience severe financial hardship as a result of these exorbitant expenses, especially in areas with low and moderate incomes where access to cutting-edge treatments may be of Early DiagnosisIn its early stages, patients may not detect any signs of age-related macular degeneration (AMD), which frequently develops slowly. Because of this, many people wait until they have experienced severe vision loss before seeking medical help. Early detection can be difficult due to the disease's sluggish progression, and by the time patients receive a diagnosis, the illness is frequently well advanced. Company Analysis: Overview, Key Persons, Recent Development & Strategies, Financial Insights Hoffmann - La Roche Ltd. Bayer AG Abbvie GSK Plc Novartis AG Regeneron Pharmaceuticals Bausch Health Companies Inc. Alimera Sciences Inc. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $11.42 Billion Forecasted Market Value (USD) by 2033 $20.88 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Age-Related Macular Degeneration Market6. Market Share6.1 Disease Type6.2 Product6.3 Distribution Channel6.4 Country7. Disease Type7.1 Dry Age-Related Macular Degeneration Market7.2 Wet Age-Related Macular Degeneration Market8. Product8.1 Eylea8.2 Lucentis8.3 Beovu8.4 Others9. Distribution Channel9.1 Hospital Pharmacy9.2 Specialty Pharma9.3 Online Pharmacy10. Country10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 UAE11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Age-Related Macular Degeneration (AMD) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
